Protara Therapeutics, Inc. - Common Stock (TARA)

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

TARA-002, a cell-based therapy by Protara Therapeutics, shows promising results in treating lymphatic malformations in pediatric patients.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Protara Therapeutics reports promising Phase 2 results for TARA-002 in bladder cancer patients, highlighting high response rates and strong safety data.

TARA stock results show that Protara Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

TARA stock results show that Protara Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics' advancements in cancer therapy and FDA alignment for Choline Chloride.